Strides Pharma gets USFDA nod to market HIV drug
Strides Pharma Science said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Shares of Strides Pharma Science ended 2.51 per cent up at Rs 508.20 apiece on the BSE on Wednesday. Pic: strides.com